icon_loop icon_cart icon_arrow-down icon_pick-winners icon_make-better-decisions icon_gofaster-gosmarter icon_equio icon_custom-research icon_conquer-the-wild icon_be-anonymous-and-secure icon_analyst-reports icon_access-realtime-data icon_youtube icon_twitter icon_linkedin icon_facebook

Significant Growth is Expected with Branded Marijuana-Derived CBD Products

 

  • The CBD Report 2018: Industry Outlook, details how the U.S. CBD industry grew nearly 40% in 2017, reaching $367 million in sales across both hemp-derived and marijuana-derived markets.
  • For the first time in 2017, U.S. hemp-derived CBD products outsold marijuana-derived CBD products.
  • Marijuana-derived CBD branded sales grew from $64M in 2016 to $118M in 2017, a one-year increase of 84%.  They will account for nearly 80% of the market versus flower by 2020.
  • The anticipated rollout of Epidiolex in September will open the pharmaceutical channel; by 2022 the juvenile epilepsy treatment will account for approximately 1/3 of the total CBD market, netting estimated sales of over $625M.

 

Leave a Reply

Your email address will not be published. Required fields are marked *